With $SOPH being one of the more bullish charts on my radar, decided to do a deep dive in to the stock. $SOPH Thesis: The AI data flywheel in precision medicine that’s still under the radar SOPHiA GENETICS isn’t a sequencing company. It’s the cloud-native AI layer that turns multimodal data (genomics + radiomics + clinical + pathology) into actionable insights for cancer and rare diseases. The Moat - 2.3M+ genomic profiles analyzed and growing • 537+ core institutions across 75 countries (including multiple top cancer centers) - Self-reinforcing data network: more analyses → smarter algorithms → stickier customers • 75%+ adjusted gross margins and <1% annualized churn - Net dollar retention 117% The Numbers Q1 2026: Revenue $21.7M (+22% YoY), analysis volume +16%. Full-year 2026 guide: $92–94M revenue (+20–22%) and adjusted EBITDA loss narrowing to $29–32M. Management targeting adjusted EBITDA breakeven by end of 2026 and positive in H2 2027. They just closed a $57.5M oversubscribed offering and transitioned leadership — Ross Muken (former President) is now CEO, founder moves to Executive Chairman. Balance sheet is cleaner. Why it can work Sequencing costs keep falling while data complexity explodes. Hospitals and labs need software that actually works across instruments and modalities. SOPHiA is technology-agnostic, already deployed at scale, and expanding into high-value areas like liquid biopsy (MSK-ACCESS partnership) and biopharma collaborations ($AZN and others). U.S. is still under-penetrated. Average revenue per customer has room to expand meaningfully as they land-and-expand. The Setup~ $480M market cap. Trading at a reasonable multiple for a high-margin AI healthcare platform with clear path to profitability and a real data advantage. Analyst targets cluster around $8. Risks Still loss-making. Competition is real ($TEM, $GH $ILMN ecosystem, etc.). Execution on new go-lives and U.S. growth matters. Dilution risk remains if they need more capital. Sentiment in healthcare AI can swing hard. This is a classic “prove the model, then the multiple expands” story. Data flywheel + improving unit economics + secular AI + precision medicine tailwinds. $SOPH continues it's breakout from the level in my analysis below with daily, weekly, monthly time frames all aligned as strong buys.